COURAGE-ALS Trial of Reldesemtiv to Continue After Interim Analysis
The COURAGE-ALS Phase 3 trial of Cytokinetic’s experimental therapy reldesemtiv in people with amyotrophic lateral sclerosis (ALS) will continue as planned following its first planned interim analysis. A data monitoring committee met to review the trial’s data so far with the goal of assessing futility, or whether the…